A phase III trial that ends this early? Who'd have thought it was possible. It's truly mind-blowing. With a blockbuster drug like Nexavar as a competitor, it's time to admit defeat, and get back to the drawing board.
Look out below.
PGL Price at posting:
0.0¢ Sentiment: Buy Disclosure: Held
